T-knife Therapeutics Files Clinical Trial Application for Phase 1 ATLAS Trial for TK-6302, a Supercharged PRAME-targeted T Cell Receptor Therapy

-- Preclinical data with TK-6302 has shown best-in-class anti-tumor efficacy, demonstrating its potential to elicit deep and durable responses in diverse solid tumor indications with high unmet need

-- Following CTA approval, Phase 1 ATLAS trial planned to begin in 2026

SAN FRANCISCO and BERLIN, Nov. 17, 2025 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company developing next-generation T cell therapies to fight cancer, today announced the filing of a Clinical Trial Application (CTA) to begin the Phase 1 ATLAS trial for TK-6302, a Supercharged PRAME-targeted TCR T cell therapy in solid tumors. PRAME is a validated target expressed in multiple solid tumor indications with high unmet need, including squamous non-small cell lung, ovarian, endometrial, skin, and triple negative breast cancers.

“The filing of this clinical trial application is a notable achievement, both for the development of TK-6302 and for our company,” stated Thomas M. Soloway, President and Chief Executive Officer of T-knife. “This milestone reflects the unwavering commitment of our employees to boldly innovate and redefine solutions in the service of solid tumor patients. We have pioneered novel technologies with TK-6302 that demonstrate best-in-class preclinical results in enhancing T cell fitness, persistence and anti-tumor activity, while overcoming immune barriers. Empowered by these novel advances, we are excited by the prospect of initiating the ATLAS trial to evaluate the potential of TK-6302.”

TK-6302 is a PRAME-targeted TCR-T that has been “supercharged” by the inclusion of key differentiating innovations: a high affinity TCR to enhance cytotoxicity; a costimulatory CD8 coreceptor to engage CD4 T cells and enhance T cell fitness and persistence; and a FAS-based checkpoint converter designed to boost engraftment and promote T cell survival in the hostile tumor micro-environment. Preclinical data with TK-6302 demonstrated sustained serial killing and cytokine secretion in a model mirroring the inhibitory ligand expression in PRAME-expressing tumors. In a complex 3-dimensional (3D) spheroid tumor model, TK-6302 eliminated multiple rounds of tumors and demonstrated superior anti-tumor activity compared to controls. TK-6302 is manufactured with a non-viral gene editing process for improved TCR expression, and it has been successfully manufactured at-scale using the clinical process.

About T-knife Therapeutics
T-knife is a biopharmaceutical company dedicated to developing T cell therapies to deliver broad, deep and durable responses to solid tumor cancer patients. The company’s unique approach leverages its proprietary platforms and synthetic biology capabilities to design the next-generation of supercharged T cells with best-in-class potential.

The company’s lead program, TK-6302, is a supercharged PRAME targeting TCR-T that includes novel enhancements to improve T cell fitness and persistence, to overcome the immunosuppressive tumor micro-environment, and to improve durability of response. Following CTA approval, the company plans to initiate the ATLAS Phase 1 clinical trial of TK-6302 in 2026.

T-knife was founded by leading T cell and immunology experts utilizing technology developed at the Max Delbrück Center for Molecular Medicine together with Charité – Universitätsmedizin Berlin, is led by an experienced management team, and is supported by a leading group of international investors, including Andera Partners, EQT Life Sciences, RA Capital Management and Versant Ventures. For additional information, please visit the company’s website at www.t-knife.com.

T-knife Therapeutics, Inc. 
Camille Landis  
Chief Business Officer / Chief Financial Officer 
media@t-knife.com  

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.